title: Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines.
abstract: OBJECTIVE
  This study evaluated the cytotoxicity of five prostaglandin analog ophthalmic solutions on four ocular surface cell lines, ie, Chang (human conjunctiva), SIRC (rabbit cornea), RC-1 (rabbit cornea), and BCE C/D-1b (bovine cornea).
  
  
  METHODS
  Cell viability was measured by neutral red and MTT assays in cells treated for 10, 30, or 60 minutes with various doses of prostaglandins (undiluted, and 2- and 10-fold dilutions). The number of cell lines with viability >/=50% in the presence of selected dilution of the drug (CVS(50)) was used for comparison. In addition, 24 cell viability comparisons (four cell lines, two assays, and three exposure times) were made between latanoprost (Xalatan((R))) and each other solution at each dose. A comparison between the newly introduced tafluprost (Tapros((R))) with 0.01% benzalkonium chloride was also made.
  
  
  RESULTS
  The order of cell viability determined by CVS(50) was Travatan Z((R)) (travoprost with the SofZia system) > Tapros >/= Travatan((R)) (travoprost) = Xalatan > Rescula((R)) (unoproston). This was consistent with the results of direct comparisons between Xalatan and the other drugs. There was no clear difference in cell viability between Tapros and benzalkonium chloride.
  
  
  CONCLUSIONS
  Use of two assays, multiple cell lines, and various dilutions and exposure times provided a unique evaluation of cytotoxicity among ophthalmic solutions. CVS(50) was useful for comparison of the cell viability of the solutions.
authors.affiliation: Department of Ophthalmology, Saitama National Hospital, Wako City, Saitama, Japan. mayaki@olive.ocn.ne.jp
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ayaki
authors.forename: Atsuo
authors.initials: A
authors.lastname: Iwasawa
references.citation: J Ocul Pharmacol Ther. 2003 Feb;19(1):23-35
references.pmid: 12648301
references.citation: Ophthalmology. 1996 Jan;103(1):138-47
references.pmid: 8628544
references.citation: Clin Exp Ophthalmol. 2008 Aug;36(6):553-9
references.pmid: 18954319
references.citation: Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619-30
references.pmid: 10067965
references.citation: Am J Ophthalmol. 2003 May;135(5):688-703
references.pmid: 12719078
references.citation: Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4123-8
references.pmid: 17724196
references.citation: Exp Eye Res. 2000 Jan;70(1):113-20
references.pmid: 10644427
references.citation: Br J Ophthalmol. 2007 May;91(5):673-6
references.pmid: 17124244
references.citation: Lancet. 2004 May 22;363(9422):1711-20
references.pmid: 15158634
references.citation: Arch Ophthalmol. 2004 Feb;122(2):185-9
references.pmid: 14769594
references.citation: Br J Ophthalmol. 2008 Sep;92(9):1275-82
references.pmid: 18723745
references.citation: Exp Eye Res. 2000 May;70(5):563-9
references.pmid: 10870514
references.citation: J Ocul Pharmacol Ther. 2008 Oct;24(5):521-6
references.pmid: 18808364
references.citation: Curr Eye Res. 2008 Apr;33(4):303-12
references.pmid: 18398704
references.citation: Exp Eye Res. 1999 Oct;69(4):431-6
references.pmid: 10504276
references.citation: Ophthalmology. 2004 Mar;111(3):427-34
references.pmid: 15019314
references.citation: Invest Ophthalmol. 1976 Apr;15(4):246-59
references.pmid: 1262158
references.citation: Adv Ther. 2003 Jan-Feb;20(1):1-13
references.pmid: 12772813
references.citation: Am J Ophthalmol. 2003 Mar;135(3):314-20
references.pmid: 12614748
references.citation: Invest Ophthalmol Vis Sci. 2004 May;45(5):1360-8
references.pmid: 15111589
references.citation: Cornea. 2008 Apr;27(3):339-43
references.pmid: 18362664
references.citation: Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4594-9
references.pmid: 16303954
references.citation: Clin Ophthalmol. 2010 Sep 20;4:1019-24
references.pmid: 20922036
references.citation: Surv Ophthalmol. 1997 Feb;41 Suppl 2:S129-38
references.pmid: 9154289